Search results
Results from the WOW.Com Content Network
Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder. It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time.
fewer side effects than short-acting Oxybutynin; 2 pills per day; 10% of Caucasians and 19% of black people have a genetic difference which causes them to lack a certain enzyme. Lack of this enzyme makes the drug less effective. Tolterodine (extended release) fewer side effects than short-acting Oxybutynin; 1 pill per day
A muscarinic acetylcholine receptor antagonist, also simply known as a muscarinic antagonist or as an antimuscarinic agent, is a type of anticholinergic drug that blocks the activity of the muscarinic acetylcholine receptors (mAChRs). The muscarinic receptors are proteins involved in the transmission of signals through certain parts of the ...
The drug is expelled via the laser-drilled hole visible on the left side of the tablet. The osmotic-controlled release oral delivery system (OROS) is an advanced controlled release oral drug delivery system in the form of a rigid tablet with a semi-permeable outer membrane and one or more small laser drilled holes in it.
Effects of anticholinergic drugs include: Delirium (often with hallucinations and delusions indistinguishable from reality); Ocular symptoms (from eye drops): mydriasis, pupil dilation, and acute angle-closure glaucoma in those with shallow anterior chamber [11] [12] [13]
Template:Androgen/anabolic steroid dosages for breast cancer References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).
Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M 3 and M 1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body. [medical citation needed]
Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder. [1] [2] [3] It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis.